Exclusive Colon CAD Research Collaboration with Leading US CT Colonography Radiologists Dr. Perry Pickhardt and Dr. David Kim

Thursday, June 5, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 4 Medicsight PLC (AIM: MDST), asubsidiary of MGT Capital Investments, Inc. (Amex: MGT) (the "Company"), andan industry leader in the development of Computer-Aided Detection (CAD) andimage analysis software, today announces the signing of an exclusive CADclinical research agreement with leading US CT Colonography radiologists, Dr.Perry Pickhardt and Dr. David Kim, from the University of Wisconsin MedicalSchool, Madison, WI.

Dr. Pickhardt, Associate Professor of Radiology and Dr. Kim along with TheUniversity of Wisconsin were the first group to establish a third-partyreimbursed CT colonography colorectal cancer screening programme in 2004.Since then they have both played an instrumental role in building the clinicalevidence base that has proven the comparable effectiveness of CTC for thedetection of colorectal neoplasia within an asymptomatic population inrelation to Optical Colonoscopy. A key milestone recently achieved, partly asa result of their research, was the release of the American Cancer Society2008 Consensus Guidelines that focus on colon cancer prevention and for thefirst time have recommended CTC be provided every five years for adults aged50 years and over.

Commenting on the collaboration, Dr. Perry Pickhardt said, "Dr. Kim and Iare excited about the Medicsight CAD research collaboration. This workpromises to further improve the clinical performance of CAD and help defineits role within colon cancer screening programmes in the USA."

David Sumner, CEO of Medicsight, commented, "I am delighted that PerryPickhardt and David Kim, global leaders in CTC and radiology, have enteredinto this exclusive research agreement with Medicsight. Their specialistadvice and vast experience of CTC practice will greatly enhance the clinicalvalidation of Medicsight's ColonCAD products set in the context of the world'slargest healthcare market. As a company we underpin all our efforts with bestof breed clinical research. This research partnership clearly demonstratesthis fact to both our partners and their customers alike."

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc is a technology holding company that focuseson investments in the global healthcare information technology market. TheCompany has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a leading developer of computer-aideddetection (CAD) software solutions. Medicsight's CAD solutions help cliniciansutilizing Computed Tomography (CT) scans to identify, measure and analyzesuspicious pathology within the colon and lungs. The Medicsight CAD productsare validated against one of the world's largest databases of verified CT scandata collected from leading healthcare institutions from around the world.Medicsight products allow radiologists and physicians to review scans morequickly and accurately -- saving both time and lives

Medicexchange PLC provides medical imaging professionals with a global webportal containing an online sales, jobs and information channel fordiagnostic, treatment and surgery planning solutions. This combined with avariety of relevant clinical papers, training materials and content givesthese professionals access to information and products that they otherwisewould have difficulty accessing.

Additional information can be found at www.mgtci.com .

All forward-looking statements are made pursuant to the 'safe harbor'provisions of the Private Securities Litigation Reform Act of 1995.Forward-looking statements are based on current management expectations thatinvolve risks and uncertainties that may result in such expectations not beingrealized. Potential risks and uncertainties include, but are not limited to,the risks described in company filings with the Securities and ExchangeCommission.

SOURCE MGT Capital Investments, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store